<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863056</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1453</article-id><article-id pub-id-type="other">EPV0831</article-id><article-id pub-id-type="pii">S0924933824014536</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Importance of the type of pharmacological treatment in patients with severe mental disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lucas</surname><given-names>M.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Romero</surname><given-names>P.</given-names></name><xref rid="aff3192" ref-type="aff"/><xref rid="cor1303" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sirvent</surname><given-names>N.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Roig</surname><given-names>R.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Baj&#x000e9;n</surname><given-names>J.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Ali&#x000f1;o</surname><given-names>M.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Escobar</surname><given-names>C.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez</surname><given-names>C.</given-names></name><xref rid="aff3192" ref-type="aff"/></contrib></contrib-group><aff id="aff3192">PSYCHIATRIC, <institution>SESCAM</institution>, <city>ALBACETE</city>, <country>Spain</country></aff><author-notes><corresp id="cor1303"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1428">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S698</fpage><lpage>S699</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824014536a.pdf"/><abstract><sec id="sec7833"><title>Introduction</title><p>
The use of long-acting treatments is a common clinical practice in psychiatry. No disease insight and the risk of treatment discontinuation in a significant portion of our patients, increase the demand for psychiatric emergency and hospital admissions. Treatment adherence must be facilitated, taking into account possible side effects and patient&#x000b4;s subjective satisfaction.</p></sec><sec id="sec7834"><title>Objectives</title><p>-Evaluate the type of long-acting intramuscular treatment in selected patients. -Evaluate the differences in treatment satisfaction between different types of long-acting intramuscular treatments as well as frequency of psychiatric emergency and hospital admissions in the last year.</p></sec><sec id="sec7835"><title>Methods</title><p>We select patients with different severe mental disorders who stay in a Medium Stay Unit, Sociosanitary Community Residence, Supervise house and Residence for the elderly in Albacete (Spain); all of them, with intramuscular neuroleptic treatment (zuclopenthixol dihydrochloride, aripiprazole long acting, palmitate paliperidone monthly, 3-monthly and 6-monthly) at least 1 year.</p><p>We evaluate their sociodemographic characteristics, the satisfaction questionnaire with the treatment (TSQM-9) and the rate of psychiatric emergencies and admissions after current intramuscular treatment in last year.</p></sec><sec id="sec7836"><title>Results</title><p>We have selected 57 patients with an average age of 45.86. 78.94% with a diagnosis of schizophrenia, 12.28% with schizoaffective disorder, 5.26% bipolar disorder and 3.5% unspecified psychotic disorder.</p><p>We can see in the graphics below that the longer duration of the intramuscular treatment, the greater satisfaction in all the items of the TSQM-9 questionnaire.</p><p>
31% of the patients with zuclopenthixol dihydrochloride treatment, have gone to psychiatric emergencies and 28% of psychiatric admissions in the last year.18% of the patients with aripiprazole long acting, 17% with paliperidone palmitate long acting-monthly and 12% de 3-monthly have gone to psychiatric emergencies and 15%, 12% and 12% needed psychiatric admissions respectively. Patients with palmitate long acting-monthly have not emergencies or psychiatric admissions in the last year.</p><p>
<bold>Image:</bold>
</p><p>
<fig position="float" id="fig0160"><graphic xlink:href="S0924933824014536-FIG0160" position="anchor"/></fig>
</p><p>
<bold>Image 2:</bold></p><p>
<fig position="float" id="fig0161"><graphic xlink:href="S0924933824014536-FIG0161" position="anchor"/></fig>
</p><p>
<bold>Image 3:</bold></p><p>
<fig position="float" id="fig0162"><graphic xlink:href="S0924933824014536-FIG0162" position="anchor"/></fig>
</p></sec><sec id="sec7837"><title>Conclusions</title><p>
<list list-type="bullet"><list-item><p>
The longer long acting of the intramuscular treatments, the better patient satisfaction.</p></list-item><list-item><p>
With the longer duration treatment (Palmitate paliperidone LD 6 month), we have lower psychiatric emergencies and hospital admissions.</p></list-item></list></p></sec><sec id="sec7838"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>